Clinical Trials Logo

FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma clinical trials

View clinical trials related to FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03300557 Active, not recruiting - Clinical trials for FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Start date: November 15, 2017
Phase: Phase 2
Study type: Interventional

This pilot phase IIa trial studies how well exemestane works in treating patients with complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or low grade endometrial cancer. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02397083 Active, not recruiting - Clinical trials for Atypical Endometrial Hyperplasia

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

LEVER
Start date: September 23, 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well levonorgestrel-releasing intrauterine system works when given alone or with everolimus in treating patients with atypical hyperplasia (a pre-cancerous growth of the lining of the uterus) or stage IA grade 1 endometrial cancer. The levonorgestrel-releasing intrauterine system is designed to prevent pregnancy by releasing a hormone called levonorgestrel, which is a type of progesterone. Progesterone is a common type of hormone that is used to prevent pregnancy and may prevent or slow tumor cell growth. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether the levonorgestrel-releasing intrauterine system works better with or without everolimus in treating patients with atypical hyperplasia or stage IA grade 1 endometrial cancer.